Almost all life science companies want to break into the American market. What are the economic, strategic, and political reasons behind this? Hanna Sjöström, CEO of Neola Medical, discusses both what attracts in the USA and what decisions the government would need to make to capitalize on the Swedish life science miracle.
In part four of BioStock’s video podcast, Sonja Schwarzenberger and Hanna Sjöström delve deep into why Swedish innovations disappear westward instead of reaching Swedish patients, about the benefits of the American market, how to get there, and the most common mistakes along the way.
Listen to the podcast here: Health and Wealth – BioStock